Memorial Sloan Kettering Cancer Center
The researchers are doing this study is to find the highest dose of cytokine-induced memory-like (CIML) natural killer (NK) cells in combination with the drug atezolizumab that causes few or mild side effects in people with relapsed/refractory acute myelogenous leukemia (AML). The researchers will also look at whether the treatment combination works against participants' cancer.
Inclusion Criteria: Disease specific inclusion criteria: * Subjects must have histologically confirmed acute myeloid leukemia that meets any of the following criteria: * Refractory to at least two attempts at prior induction therapy. An attempt is defined as either a single cycle of combination chemotherapy such as daunorubicin/anthracycline OR a single monthly cycle of a hypomethylating agent with venetoclax. * Patients with FLT3-ITD or -TKD mutations must have received at least one commercially available inhibitor of FLT3. * Patients with NPM1 mutation or rearrangements of MLL must…
Subjects will receive subcutaneous recombinant human IL-2 (rh-IL2) every other day x 6 doses beginning on day 0 via subcutaneous injection.
Single dose of Atezolizumab IV over 60 minutes IV.
CIML-NK cell therapy as an intravenous (IV) infusion